PAO Group anticipates reporting an estimated $50,000 in revenue for Q4 2020.

The revenue is anticipated from a $300,000 sales agreement executed by PAOG's cannabis cultivation subsidiary.

"Last summer, PAOG acquired a cannabis cultivation business from Puration," PAOG team explains. "The acquisition was made in conjunction with PAOG's overall strategy to refresh and renew its overall cannabis healthcare industry strategy."

Last year, also in conjunction PAOG's plan to refresh and renew its overall cannabis healthcare industry strategy, the company with PAOG acquired RespRx from Kali-Extracts. RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."

PAOG anticipates approximately $50,000 in revenue per quarter for the next six quarters from the aforementioned $300,000 sales agreement.

For more information:
PAO Group
paogroupinc.com